Hansoh Pharma (03692): Single drug treatment of Alectinib Hydrochloride tablets approved and launched in the European Union.

HANSOH PHARMA (03692) announced that on February 12, 2026, the group's innovative drug, Ameitini Hydrochloride Tablet (Chinese trade name: Amele; overseas trade name: Aumseqa), has been approved for marketing in the European Union. It is used for: (i) first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations, and (ii) treatment of adult patients with advanced NSCLC with EGFR T790M mutation positivity. This approval by the European Commission (EC) was based on the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).